Conant v. Walters

Background: Proposition 215 and the federal response

In November 1996, California voters passed Proposition 215, the Compassionate Use Act, making California the first U.S. state to legalize medical cannabis ^[1]. The law permitted patients to possess and cultivate cannabis with a physician's 'recommendation' — a term chosen deliberately by drafters because a written 'prescription' for a Schedule I drug would contradict federal law.

The Clinton administration responded quickly. On December 30, 1996, drug czar Barry McCaffrey, Attorney General Janet Reno, and HHS Secretary Donna Shalala announced at a press conference that any physician recommending cannabis to a patient risked losing their DEA registration, exclusion from Medicare and Medicaid, and potential prosecution ^[2]. For most physicians, losing a DEA registration is effectively disqualifying from practice.

This federal threat was a direct response to Proposition 215. The intent was to deter physicians from making recommendations and thereby undermine the state law's practical effect.

The plaintiffs and the lawsuit

In February 1997, a class of California physicians and patients filed suit in the U.S. District Court for the Northern District of California challenging the federal policy on First Amendment grounds. The lead plaintiff was Dr. Marcus Conant (1936–2021), a dermatologist and prominent AIDS physician in San Francisco who had been recommending cannabis to patients with wasting syndrome since the 1980s. Co-plaintiffs included other physicians treating cancer and HIV patients.

The plaintiffs were represented by Graham Boyd and attorneys from the ACLU Drug Policy Litigation Project. Their argument was precise: the case was not about whether cannabis worked medically, whether patients had a right to use it, or whether states could legalize it. The argument was that the federal government violated the First Amendment by threatening to punish physicians for the content of doctor-patient conversations about cannabis.

Judge Fern Smith issued a preliminary injunction in April 1997, blocking enforcement of the federal threat. Judge William Alsup made the injunction permanent in 2000 ^[3].

The Ninth Circuit decision

The government appealed to the U.S. Court of Appeals for the Ninth Circuit. By the time oral arguments occurred, John Walters had replaced McCaffrey as Director of the Office of National Drug Control Policy, and the case caption was updated accordingly.

On October 29, 2002, a three-judge panel — Judges Mary Schroeder, Betty Fletcher, and Alex Kozinski — unanimously affirmed the injunction ^[4]. The court held that a physician's recommendation of cannabis in the doctor-patient relationship is speech protected by the First Amendment. The government retained the power to prosecute physicians who actually conspired with patients to obtain or distribute cannabis, but it could not punish speech itself.

Judge Kozinski's concurrence is the most extensively cited portion of the opinion. He discussed the reality that millions of Americans were using cannabis medically, that the federal Schedule I classification ("no accepted medical use in treatment") was increasingly misaligned with state law and clinical practice, and that physicians needed to discuss cannabis candidly with patients ^[5].

The Supreme Court declined certiorari in October 2003, leaving the Ninth Circuit ruling in place ^[6]. While the ruling is technically binding only in the Ninth Circuit (covering California, Nevada, Arizona, Hawaii, Guam, and the Northern Mariana Islands), no other circuit court has subsequently ruled against physician speech protections in similar cases, and the federal government has not publicly attempted to revoke a DEA license solely for a cannabis recommendation since the decision.

Scope and limitations

It is important to distinguish what Conant protected from what it did not:

What Conant protected:

• Physician speech recommending cannabis to patients in a bona fide doctor-patient relationship
• Physicians from DEA licensing retaliation based solely on that speech

What Conant did not do:

• Legalize cannabis under federal law. Cannabis remained Schedule I Strong evidence ^[1].
• Protect patients from federal prosecution for possessing or using cannabis. That issue was addressed separately in Gonzales v. Raich (2005), where the Supreme Court upheld federal authority to prosecute patients Strong evidence ^[7].
• Protect cannabis dispensaries, growers, or cultivators. Those operations remained federally illegal.
• Require physicians to recommend cannabis or insurers to cover it.
• Establish a constitutional right to medical cannabis or supersede state discretion over medical licensure.

The injunction applies narrowly to the federal government's threat to revoke DEA registrations. State medical boards retain independent authority to discipline physicians under state law, and many have separate rules governing cannabis recommendations.

Role in state medical-cannabis programs

All U.S. state medical-cannabis programs that have been established since 1996 rely on a physician 'recommendation' or 'certification' rather than a 'prescription.' This distinction exists because federal law classifies cannabis as Schedule I, making a prescription technically impossible under the Controlled Substances Act. Conant secured the legal space for these recommendation-based frameworks by preventing the federal government from using DEA license revocation to suppress physician participation.

However, Conant did not create state medical-cannabis programs. State programs were established by state legislatures or ballot initiatives under state law, and they operate independently of federal protections. Conant removed one federal barrier to physician participation but did not mandate or enable state programs in other respects. States retain the authority to set eligibility criteria, regulate dispensaries, and establish their own restrictions on physician speech about cannabis.

Key figures and legal context

Dr. Marcus Conant (1936–2021): A San Francisco dermatologist and early AIDS researcher who treated some of the first recognized AIDS patients in the United States. Conant observed that cannabis reduced nausea and appetite loss in wasting-syndrome patients and began recommending it in the 1980s, decades before Proposition 215. He remained publicly associated with medical-cannabis advocacy for the rest of his life.

Barry McCaffrey (1942–): Director of the Office of National Drug Control Policy ("drug czar") under President Clinton, 1996–2001. McCaffrey orchestrated the federal response to Proposition 215 and Arizona's Proposition 200 (which passed the same day).

John Walters (1950–): McCaffrey's successor as ONDCP Director under President George W. Bush, 2001–2009. Walters defended the federal policy on appeal.

Graham Boyd (1959–): Lead counsel for the plaintiffs, representing the ACLU Drug Policy Litigation Project. Boyd was a pioneering civil-rights litigator who brought multiple First Amendment and Fourth Amendment cases related to drug policy.

Judge Alex Kozinski (1950–): Author of the influential concurrence. Kozinski is known for scholarly concurrences and dissents addressing the tension between federal law and state practice.

Sources

How this page was made